Phase IIa trial of IDX 719 + simeprevir + ritonavir-boosted TMC 647055 with or without ribavirin for treatment-naive patients with hepatitis C infection (HELIX-2)

Trial Profile

Phase IIa trial of IDX 719 + simeprevir + ritonavir-boosted TMC 647055 with or without ribavirin for treatment-naive patients with hepatitis C infection (HELIX-2)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Nov 2014

At a glance

  • Drugs Samatasvir (Primary) ; Simeprevir (Primary) ; TMC 647055 (Primary) ; Ribavirin; Ritonavir
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms HELIX-2
  • Most Recent Events

    • 01 May 2014 According to an Idenix Pharmaceuticals media release, sustained virological response rate (SVR4) data will be reported in the second-half of 2014.
    • 02 Dec 2013 Idenix MR, same as 9156943.
    • 02 Dec 2013 Status changed from planning to recruiting, according to a Medivir AB media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top